Page last updated: 2024-09-04

vatalanib and Primary Myelofibrosis

vatalanib has been researched along with Primary Myelofibrosis in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Albitar, M; Carroll, M; Chen, BL; Cortes, JE; Feldman, EJ; Giles, FJ; Jacques, C; Laurent, D; List, AF; Masson, E; Roboz, GJ; Valickas, J	1

Trials

1 trial(s) available for vatalanib and Primary Myelofibrosis

Article	Year
PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia. Leukemia research, 2007, Volume: 31, Issue:7 Topics: Adult; Aged; Cohort Studies; Female; Humans; Male; Middle Aged; Phthalazines; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyridines; Tissue Distribution; Treatment Outcome; Vascular Endothelial Growth Factor A	2007

Article

Year

PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia.

Leukemia research, 2007, Volume: 31, Issue:7

Topics: Adult; Aged; Cohort Studies; Female; Humans; Male; Middle Aged; Phthalazines; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyridines; Tissue Distribution; Treatment Outcome; Vascular Endothelial Growth Factor A

2007